Meningococcal Meningitis
📧 Sign up to get email alerts when something new happens for Meningococcal Meningitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine [Phase 1]
This is a Phase Ia clinical trial evaluating Group ACYW135X meningococcal conjugate vaccine by Sinovac Life Sciences, with the study status …
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds [Phase 3]
Phase 3 clinical trial of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) in 7- to 17-year-olds; the study …
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
This ClinicalTrials.gov entry reports termination of a trial studying long-term sequelae after childhood meningitis and meningococcal purpur…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Sero-epidemiological Survey of England in 2019/2020 - COVID-19
Completed sero-epidemiological survey in England (2019/2020) examining COVID-19 alongside serogroup C meningococcal meningitis and diphtheri…
-
CLINICAL_TRIALS trial_result · 2024-03-29Clinical Trial Update: A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine [Phase 2]
Phase 2 clinical trial update for ACYW135 meningococcal polysaccharide conjugate vaccine.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-07Clinical Trial Update: A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years [Phase 4]
Phase 4 trial evaluating non-inferior immunogenicity of Yuxi Walvax MPV ACYW vaccine in healthy children aged 2-10 years for meningococcal m…
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea [Phase 4]
Postmarketing surveillance study (Phase 4) evaluating Menactra in the Republic of Korea has completed.
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds [Phase 2]
Phase 2 trial of the Meningococcal ACYWX Conjugate Vaccine in 12- to 16-month-old children has completed; results were posted on 2021-09-05.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) [Phase 3]
Phase 3 trial completed evaluating the immunogenicity and safety of NmCV-5, a pentavalent meningococcal vaccine.
-
CLINICAL_TRIALS trial_result · 2020-12-30Clinical Trial Update: A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine [Phase 3]
A Phase III trial update for a group A meningococcal polysaccharide vaccine; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years [Phase 3]
Phase 3 study of an investigational quadrivalent meningococcal conjugate vaccine in children aged 2 to 9 years has completed with results po…
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers [Phase 3]
Phase 3 trial assessing immunogenicity and safety of a meningococcal conjugate vaccine given concomitantly with other vaccines in toddlers; …
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents [Phase 2]
Phase 2 trial evaluating the immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in healthy adolesc…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine [Phase 3]
Phase 3 trial update on immunogenicity and safety of a booster dose for an investigational quadrivalent meningococcal conjugate vaccine; stu…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers [Phase 2]
Phase 2 trial updating immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in healthy toddlers; res…
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older [Phase 3]
Phase 3 trial assessing immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in adults 56 and older;…
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 [Phase 3]
Phase 3 trial update on antibody persistence and safety/tolerability of a booster dose for the meningococcal B vaccine after completion of t…
-
CLINICAL_TRIALS trial_result · 2018-06-20Clinical Trial Update: RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) [Phase 3]
Phase 3 trial results for a combination vaccine regimen including RotaTeq and Meningococcus C vaccine in healthy infants; results were poste…
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects [Phase 4]
Phase 4 trial update evaluating immunogenicity and safety of a two-dose Menactra series in healthy Japanese adults. The study has completed …
-
CLINICAL_TRIALS trial_result · 2016-11-07Clinical Trial Update: Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier [Phase 4]
Phase 4 trial evaluating persistence of bactericidal antibodies in adults about four years after a Menactra booster.
-
CLINICAL_TRIALS trial_result · 2016-08-26Clinical Trial Update: Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months [Phase 1]
A Phase 1 safety study of a meningococcal ACYW135 polysaccharide conjugate vaccine is being conducted in healthy volunteers aged over 3 mont…
-
CLINICAL_TRIALS trial_result · 2016-04-12Clinical Trial Update: Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study
Follow-up results show the persistence of protective antibody titers 12-24 months after NmVac4-A/C/Y/W-135-DT vaccination.
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years [Phase 3]
This is a Phase 3B open-label study evaluating the safety, tolerability, and immunogenicity of the Novartis Meningococcal B Recombinant Vacc…
-
CLINICAL_TRIALS trial_result · 2015-11-11Clinical Trial Update: Neisseria Meningitidis Burden of Disease Study
GlaxoSmithKline-sponsored burden-of-disease trial focusing on Neisseria meningitidis has completed. The study also concerns infections cause…
-
CLINICAL_TRIALS trial_result · 2015-11-10Clinical Trial Update: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluated the safety, tolerability, and immunogenicity of a Meningococcal B recombinant vaccine when given as a …